Novo Nordisk CEO Lars Fruergaard Jørgensen stated Friday that the business’s speculative weight reduction tabletAmycretin, “might turn into a best-in-class medication.” His discuss CNBC came a day after the business’s stock rose following the statement of appealing outcomes for the drug. That sent out Novo Nordisk’s market cap past Tesla’s and made it the 12th-most important business worldwide.
Will Ozempic truly take control of America?|What’s Next for Novo Nordisk?
The drug maker informed financiers on Thursday that Amycretin assisted users lose approximately 13% of body weight after 12 weeks in an early-stage trial. By contrast, clients on the diabetes weight-loss drugs Ozempic and Wegovy, both of which are injections, lose about 6% of their weight in 12 weeks.
Jørgensen informed CNBC on Friday that the he does not anticipate Amycretin to totally change Wegovy in the market.
“We think in the future, there will be various sectors of anti-obesity treatments, various clients having various choices,” Jørgensen stated. “Some will choose an injectable. And we truly think that a once-weekly injectable is an extremely hassle-free offering.”
It will take Novo Nordisk years to satisfy complete need for weight reduction drugs
Jørgensen likewise stated the space in between need for weight reduction drugs and the supply is considerable and might take the market years to close.
He explained that there are more 100 million individuals with weight problems in the U.S. alone. Novo Nordisk presently just serves a little population of that group, about 1 million.
“It’ll take rather some years before the market has actually scaled up products to be able to fulfill this really strong need,” Jørgensen stated.
Novo Nordisk revealed in February that it has purchased 3 centers from the drug producing business Catalent for $11 billion in an effort to deal with a scarcity of Wegovy. As part of the deal, the business’s biggest investor Novo Holdings consented to get Catalent. Novo Nordisk stated in a declaration that the acquisition will increase the business’s production capability from 2026 and onwards.
Given that May 2023, Novo Nordisk has actually been restricting starter dosages of Wegovy to guarantee there suffices supply for clients currently on the drug.